Q2 2025 EPS Estimates for Hologic, Inc. (NASDAQ:HOLX) Lifted by Analyst

Hologic, Inc. (NASDAQ:HOLX - Free Report) - Equities research analysts at Zacks Research lifted their Q2 2025 earnings per share estimates for Hologic in a research report issued on Wednesday, April 10th. Zacks Research analyst R. Anand now expects that the medical equipment provider will post earnings per share of $1.11 for the quarter, up from their prior estimate of $1.10. The consensus estimate for Hologic's current full-year earnings is $4.02 per share. Zacks Research also issued estimates for Hologic's FY2025 earnings at $4.28 EPS.

Hologic (NASDAQ:HOLX - Get Free Report) last announced its earnings results on Thursday, February 1st. The medical equipment provider reported $0.98 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.95 by $0.03. The firm had revenue of $1.01 billion during the quarter, compared to analyst estimates of $989.32 million. Hologic had a return on equity of 18.91% and a net margin of 12.98%. The business's revenue was down 5.7% compared to the same quarter last year. During the same period last year, the firm posted $1.07 EPS.

Other equities analysts have also issued reports about the company. William Blair reissued an "outperform" rating on shares of Hologic in a report on Friday, February 2nd. Evercore ISI lifted their price objective on Hologic from $76.00 to $78.00 and gave the stock an "in-line" rating in a report on Thursday, April 4th. Citigroup upgraded Hologic from a "neutral" rating to a "buy" rating and boosted their price objective for the company from $80.00 to $95.00 in a research note on Wednesday, April 3rd. StockNews.com lowered shares of Hologic from a "buy" rating to a "hold" rating in a research report on Friday, March 8th. Finally, Raymond James boosted their price target on shares of Hologic from $85.00 to $88.00 and gave the company an "outperform" rating in a research report on Friday, February 2nd. Six analysts have rated the stock with a hold rating and four have given a buy rating to the company. According to data from MarketBeat.com, the stock currently has a consensus rating of "Hold" and an average price target of $87.00.

Hologic Stock Performance

Shares of Hologic stock traded up $0.21 on Monday, reaching $77.54. 1,605,404 shares of the company traded hands, compared to its average volume of 1,816,235. The company has a 50 day moving average of $75.64 and a 200 day moving average of $72.42. The company has a debt-to-equity ratio of 0.55, a current ratio of 3.89 and a quick ratio of 3.18. Hologic has a 52 week low of $64.02 and a 52 week high of $87.88. The firm has a market capitalization of $18.20 billion, a PE ratio of 36.75, a PEG ratio of 2.62 and a beta of 1.00.

Insiders Place Their Bets

In related news, Director Scott T. Garrett sold 16,441 shares of Hologic stock in a transaction on Thursday, March 14th. The stock was sold at an average price of $75.50, for a total transaction of $1,241,295.50. Following the completion of the sale, the director now owns 48,611 shares of the company's stock, valued at $3,670,130.50. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. In related news, Director Scott T. Garrett sold 16,441 shares of the company's stock in a transaction that occurred on Thursday, March 14th. The shares were sold at an average price of $75.50, for a total value of $1,241,295.50. Following the transaction, the director now directly owns 48,611 shares in the company, valued at $3,670,130.50. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, CFO Karleen Marie Oberton sold 14,940 shares of the firm's stock in a transaction that occurred on Monday, January 29th. The shares were sold at an average price of $75.00, for a total transaction of $1,120,500.00. Following the completion of the sale, the chief financial officer now directly owns 103,916 shares in the company, valued at $7,793,700. The disclosure for this sale can be found here. Insiders have sold 32,846 shares of company stock worth $2,473,443 in the last three months. 1.75% of the stock is currently owned by corporate insiders.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently added to or reduced their stakes in HOLX. Macquarie Group Ltd. boosted its holdings in shares of Hologic by 227.2% in the 2nd quarter. Macquarie Group Ltd. now owns 6,284,053 shares of the medical equipment provider's stock worth $435,485,000 after purchasing an additional 4,363,687 shares in the last quarter. Norges Bank purchased a new stake in Hologic in the fourth quarter worth approximately $217,529,000. The Manufacturers Life Insurance Company boosted its stake in Hologic by 117.4% in the fourth quarter. The Manufacturers Life Insurance Company now owns 2,163,718 shares of the medical equipment provider's stock worth $154,598,000 after buying an additional 1,168,564 shares in the last quarter. Arrowstreet Capital Limited Partnership grew its position in Hologic by 110.6% during the first quarter. Arrowstreet Capital Limited Partnership now owns 1,896,174 shares of the medical equipment provider's stock valued at $145,664,000 after acquiring an additional 995,854 shares during the last quarter. Finally, Qube Research & Technologies Ltd raised its stake in shares of Hologic by 117.2% during the third quarter. Qube Research & Technologies Ltd now owns 1,378,258 shares of the medical equipment provider's stock worth $95,651,000 after acquiring an additional 743,557 shares in the last quarter. 94.73% of the stock is currently owned by hedge funds and other institutional investors.

About Hologic

Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth.